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Abstract 
Background: T h i s   p r o s p e c t i v e   o b s e r v a t i o n a l   s t u d y   e s t i m a t e d   t h e   e f f e c t   o f   p r o g n o s t i c   f a c-
tors, particularly continued smoking during therapy, on survival in advanced non-small cell 
lung cancer (NSCLC) patients receiving gemcitabine-platinum. Further, prognostic factors 
were used to build a survival model to improve prognosis prediction in naturalistic clinical 
settings.  
Methods:  Eligibility  criteria  included:  Stage  IIIB/IV  NSCLC,  no  prior  chemotherapy, and 
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. A   C o x   r e g r e s s i o n  
model was constructed and validated by randomizing patients into two datasets (Construc-
tion [C]:Validation [V]; 3:1 ratio). Country, disease stage, hypercalcemia, “N” factor, weight 
reduction, performance status, and superior vena cava obstruction were pre-defined variables 
forced into the model. Continued smoking was tested with adjustment for these variables.  
Results:  One thousand two hundred and fourteen patients (C=891 and V=323) were 
enrolled. The final predictive model, established in the Construction dataset, identified four 
significant (p≤0.05) and independent predictors of survival, which were disease stage, per-
formance status, gemcitabine-platinum regimen, an d   T -stage. Smoking during therapy was not 
significantly associated with survival (Hazard Ratio [95% CI]: 0.955 [0.572, 1.596], p=0.8618; 
versus never smokers).  
Conclusions: Although continued smoking during therapy was not significantly associated 
with s h o r t e r   s u r v i v a l ,   t h e   m o d e l   d e v e l o p e d   i n   t h i s   s t u d y   f o r m s   a n   e v i d e n c e -based approach to 
assessing prognosis in advanced stage NSCLC. 
Key words: smoking; observational; NSCLC; prognostic factors; predictive modeling. 
Background 
L u n g   c a n c e r   i s   o n e   o f   t h e   l e a d i n g   c a u s e s   o f   c a n-
cer-related  deaths  worldwide  [1-2],  with  non-small 
cell lung cancer (NSCLC) representing approximately 
75%-8 5 %   o f   a l l   t y p e s   o f   l u n g   c a n c e r   [ 3]. I n   t h e   m a j o r i t y  
o f   c a s e s ,   p a t i e n t s   w i t h   N S C L C   p r e s e n t   w i t h   l o c a l l y  
advanced (Stage III) or metastatic disease (Stage IV) 
[4].  
Smoking is the single most important cause of 
NSCLC [5-8], with approximately 85% of human lung 
cancers  arising  in  current  or  former  smokers.  No Journal of Cancer 2011, 2 
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prospective study has been published that evaluated 
t h e   e f f e c t   o f   s m o k i n g   o n   s u r v i v a l   i n   a d v a n c e d   N S C L C  
treated with chemotherapy. Furthermore, limited data 
i s   a v a i l a b l e   o n   t h e   e f f e c t   o f   s m o k i n g   o n   c h e m o t h e r a p y  
toxicity. Considering the high incidence of advanced 
s t a g e   N S C L C   a n d   t h e   c o m m o n   u s e   o f   c h e m o t h e r a p y  
i n   t h e s e   p a t i e n t s ,   t h e s e   q u e s t i o n s   a p p e a r   t o   b e   o f   m a-
jor clinical relevance. 
Numerous factors have been shown to influence 
survival  and  toxicity  in  patients  with  advanced 
NSCLC,  such  as  disease  stage,  performance  status, 
smoking, age, weight loss, and gender [5,9-12]. Addi-
tionally, molecular markers such as p53 and ras muta-
t i o n s ,   a n d   e x p r e s s i o n   o f   E R C C 1 ,   b e t a -tubulin III and 
RRM1, have been found to influence treatment out-
come [5,13-15].  
T h e   m a i n   a i m   o f   t h i s   p r o s p e c t i v e ,   o b s e r v a t i o n a l  
study was to estimate the effect of prognostic factors, 
in particular, continued smoking during therapy, on 
survival in patients with advanced NSCLC receiving 
gemcitabine-platinum  as  first-line  therapy.  Further, 
p r o g n o s t i c   f a c t o r s   i d e n t i f i e d   i n   p r e v i o u s   s t u d i e s   w e r e  
u s e d   t o   b u i l d   a   s u r v i v a l   m o d e l   w i t h   t h e   a i m   o f   i m-
proving prognosis prediction, in naturalistic clinical 
settings, in patients with advanced NSCLC who are 
receiving gemcitabine-platinum as first-line therapy.  
Methods 
Study Design 
This  prospective,  non-interventional,  interna-
tional,  observational  study  (B9E-AA-B004)  was  de-
s i g n e d   t o   e s t i m a t e   t h e   e f f e c t   o f   p r o g n o s t i c   f a c t o r s ,  
including  continued  smoking  during  therapy,  on 
treatment  outcomes  in  patients  with  advanced 
NSCLC  receiving  gemcitabine-platinum  as first-line 
therapy  as  part  of  their  routine care. To ensure this 
study  reflected  real-life clinical practice, all care pro-
vided to the patients (including visit frequency, pro-
cedures  performed  at  visits,  and  advice  regarding 
s m o k i n g   b e h a v i o r )   w a s   a t   t h e   d i s c r e t i o n   o f   t h e   p a r-
ticipating oncologist. Patients were recruited between 
June  2004  and  October  2005  from  nine  countries 
(China,  Egypt,  Israel,  Pakistan,  Poland,  Romania, 
South Korea, Taiwan, and Turkey) and were followed 
for survival until death, 18 months after the start of 
treatment,  or  lost  to follow-up. The study was con-
ducted in accordance with the ethics and regulatory 
r e q u i r e m e n t s   o f   e a c h   c o u n t r y   a n d   a l l   p a r t i c i p a n t s  
p r o v i d e d   w r i t t e n   i n f o r m e d   c o n s e n t   p r i o r   t o   e n r o l l-
ment in the study.  
Participants 
Patients were eligible if they: (a) were diagnosed 
w i t h   S t a g e   I I I B   o r   I V   N S C L C ;   ( b )   w e r e   c h e m o n a i v e ;   ( c )  
received gemcitabine in combination with platinum 
(carboplatin or cisplatin) as part of their routine care; 
(d)  had  an  Eastern  Cooperative  Oncology  Group 
( E C O G )   p e r f o r m a n c e   s t a t u s   ≤ 1 ;   a n d   ( e )   n o t simulta-
neously participating in a gemcitabine-platinum in-
terventional  study. The dosing schedule of gemcita-
bine-platinum  therapy,  use  of  concomitant  medica-
tions, supportive care measures, and all subsequent 
l i n e s   o f   t u m o r   t h e r a p y   w e r e   a t   t h e   d i s c r e t i o n   o f  the 
treating oncologist.  
Effectiveness and Safety Measures 
Eligible  participants  who  received  at  least  one 
dose of gemcitabine-platinum were evaluated for ef-
fectiveness and safety. Effectiveness was measured by 
s u r v i v a l ,   d e f i n e d   a s   t h e   t i m e   f r o m   s t a r t   o f  gemcita-
bine-p l a t i n u m   t h e r a p y   t o   t h e   d a t e   o f   d e a t h   d u e   t o   a n y  
cause. T h e   e f f e c t   o f   p r o g n o s t i c   f a c t o r s   o n   a n   o c c u r-
rence  of  any  selected  adverse  events  (AEs;  neutro-
penia,  thrombocytopenia,  reduced  haemoglobin,  in-
fection requiring hospitalisation or intravenous anti-
biotics,  respiratory  distress  syndrome,  dyspnea, 
d e a t h ,   o r   l i f e -threatening toxicity) and methylation of 
p16 and RASSF1A were assessed.  
Statistical Analyses 
Statistical  analyses  were  performed  using  the 
SAS program (Version 9, SAS Institute, Cary, NC). A 
t o t a l   o f   3 0 0 0   p a t i e n t s   w e r e   p l a n n e d   t o   b e   e n r o l l e d   w i t h  
patients  allocated  in  a  3:1  ratio  to  the  Construc-
tion:Validation  datasets  to  provide  80%  power  to 
draw the conclusion that continued smoking during 
c h e m o t h e r a p y   r e d u c e s   m e d i a n   s u r v i v a l   t i m e   b y  15% 
after balancing for clinical characteristics that have a 
statistically significant effect on survival. To  identify 
potential  prognostic  factors  associated  with  survival 
in  advanced  NSCLC  patients  treated  with  first-line 
gemcitabine-platinum, a total of 42 prognostic factors 
were analyzed. S o m e   o f   t h e   f a c t o r s   a n a l y z e d   i n   t h i s  
study were previously identified as potential prog-
nostic factors in NSCLC [17] and include: continued 
smoking  during  therapy;  number  of  cigarettes/day 
during  therapy;  baseline  smoking  level;  continuing 
smoker versus ex-smoker; heavy smoker at baseline; 
never smoked; race; country; disease stage; hypercal-
c e m i a ;   T N M   s t a g i n g   ( T ,   N ,   a n d   M ) ;   w e i g h t   l o s s   > 1 0 % ;  
performance status; superior vena cava obstruction 
present;  age  <70  years;  gemcitabine-platinum  regi-
men; largest tumor >5cm; gender; metastatic disease 
(extra-thoracic; liver; bone; brain); diagnosis (histol-
ogy);  dyspnea  present;  cough  present;  hemoptysis 
present; pain present; expectoration present; chronic 
obstructive pulmonary disease  present;  pleural  effu-
sion  present;  p16  status;  RASSF1A  status;  albumin Journal of Cancer 2011, 2 
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(normal  range  indicator);  hemoglobin;  aspartate 
aminotransferase  (AST/SGOT);  alanine  aminotrans-
ferase (ALT/SGPT); bilirubin (total); albumin; lactic 
dehydrogenase;  calcium.  Univariate  Cox  regression 
analysis was used to first assess the association be-
t w e e n   e a c h   v a r i a b l e   a n d   s u r v i v a l ,   f o l l o w e d   b y   m u l t i-
variate stepwise Cox regression analysis for variable 
selection (with entry and stay cutoff levels of 0.1). If 
information on any baseline or treatment variable was 
m i s s i n g   i n   > 1 0 %   o f   p a t i e n t s ,   t h a t   v a r i a b l e   w a s   n o t  
used to build the primary model. Results are reported 
as hazard ratios (HR) with 95% confidence intervals.  
Additional sensitivity analyses were performed 
to examine the potential impact of missing data. This 
involved effect of smoking variables adjusted in mul-
tivariate models, also for variables where >10% of the 
d a t a   w a s   m i s s i n g   u s i n g   t h e   s a m e   m o d e l   s e l e c t i o n  
process described above.  
Validation of the final predictive model was as-
s e s s e d   u s i n g   a   C o x   r e g r e s s i o n   o n   t h e   V a l i d a t i o n   d a-
t a s e t   w i t h   t h e   v a l u e s   o f   t h e   l i n e a r   p r e d i c t o r   c a l c u l a t e d  
from  the  coefficients  estimated  in  the  Construction 
dataset  [16].  Also,  predicted  one-year  survival  was 
d i r e c t l y   c o m p a r e d   w i t h   t h e   a c t u a l   o n e -year survival 
for patients in the Validation dataset. 
T h e   o c c u r r e n c e   o f   A E s   a n d   a s s o c i a t i o n   o f   p16 and 
RASSF1A methylation  to  baseline  prognostic  factors 
was  analyzed  using  a  univariate  and  multivariate 
(stepwise) logistic regression. 
Results 
Participant Characteristics and Treatments 
Baseline  clinical  and  demographic  characteris-
tics, including potentially important prognostic fac-
tors, are outlined in Table 1. Of 1214 patients enrolled 
from  nine  countries/regions,  891  (73.4%)  were  as-
signed to the Construction dataset and 323 (26.6%) to 
the Validation dataset. Patients were on average 60.5 
years of age, with 75.1% being male. Approximately 
half  of  the  patients  had  NSCLC  of  adenocarcinoma 
origin  (48.9%),  while  approximately  two-thirds  of 
p a t i e n t s   ( 6 9 . 4 % )   w e r e   a s s i g n e d   t o  gemcita-
bine-cisplatin treatment. The mean number of gemci-
tabine-platinum  cycles  received  was  3.76  (95%  CI: 
3 . 6 6 ,   3 . 8 6 ) ,   w i t h   3 4 . 1 %   o f   p a t i e n t s   r e c e i v i n g   n o   t h e r a p y  
post  gemcitabine-platinum  treatment.  Post  gemcita-
bine-platinum  treatment  therapies  are  outlined  in 
T a b l e   2 ,   w i t h   t h e   m o s t   c o m m o n   s e c o n d -line treatment 
approaches being docetaxel (18.3%) or radiotherapy 
(17.1%).  Of  the  1214  patients  enrolled,  253  (20.8%) 
w e r e   a l i v e   a t   s t u d y   c o m p l e t i o n ,   6 3 7   ( 5 2 . 5 % )   h a d   d i e d ,  
3 1 0   ( 2 5 . 5   % )   w e r e   l o s t   t o   f o l l o w -u p ,   w h i l e   d a t a   w a s   n o t  
available for 14 (1.2%). Three hundred and nineteen 
(26.3%)  patients  discontinued  study  therapy  due  to 
inadequate  response,  while  48  (4.0%)  discontinued 
study therapy due to AEs.  
Originally,  3000  patients  were  planned  to  be 
enrolled in th i s   s t u d y ;   h o w e v e r ,   b a s e d   o n   s l o w e r   t h a n  
expected  recruitment,  a  decision  was  made  to  stop 
accrual after 17 months. At the time, a total of 1214 
qualified patients had been enrolled in this study.  
 
Table 1. Baseline Characteristics of Potential Prognostic Factors (Construction and Validation Datasets)  
Characteristic  Construction Dataset 
N=891 
Validation Dataset 
N=323 
Total 
N=1214 
Country of Treatment, n(%)       
  China     208  (23.3)    92  (28.5)    300  (24.7) 
  Egypt     158  (17.7)    42  (13.0)    200  (16.5) 
  Israel     19  (2.1)    20  (6.2)    39  (3.2) 
  Pakistan     64  (7.2)    13  (4.0)    77  (6.3) 
  Poland+Romania     50  (5.6)    44  (13.6)    94  (7.7) 
  South Korea    147  (16.5)    46  (14.2)    193  (15.9) 
  Taiwan     179  (20.1)    16  (5.0)    195  (16.1) 
  Turkey    66  (7.4)    50  (15.5)    116  (9.6) 
Performance Status (ECOG), n(%)        
  0     294  (33.0)    115  (35.6)    409  (33.7) 
  1    596  (66.9)    208  (64.4)    804  (66.2) 
  Missing data     1  (0.1)    -    1  (0.1) 
Tumor Stage, n(%)        
  Stage IIIB     385  (43.2)    129  (39.9)    514  (42.3) 
  Stage IV    501  (56.2)    191  (59.1)    692  (57.0) 
  Missing data    5  (0.6)    3  (0.9)    8  (0.7) 
Age, years        
  Mean (SD)     61.0 (10.8)    59.2 (10.6)    60.5 (10.8) 
  Missing data    9 (1.0)    4 (1.2)    13 (1.1) 
Gender, n(%)        
  Female     222  (24.9)    78  (24.1)    300  (24.7) Journal of Cancer 2011, 2 
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  Male    667  (74.9)    245  (75.9)    912  (75.1) 
  Missing data    2  (0.2)    -    2  (0.2) 
Brain Metastasis, n(%)        
  No     832  (93.4)    298  (92.3)    1130  (93.1) 
  Yes    59  (6.6)    25  (7.7)    84  (6.9) 
Tumor Type, n(%)        
  Adenocarcinoma    434  (48.7)    160  (49.5)    594  (48.9) 
  Large Cell Lung Carcinoma     41  (4.6)    10  (3.1)    51  (4.2) 
  Mixed Cell Carcinoma, Lung     10  (1.1)    8  (2.5)    18  (1.5) 
  Non-small Cell Carcinoma     122  (13.7)    45  (13.9)    167  (13.8) 
  Squamous Cell Carcinoma of Lung    284  (31.9)    100  (31.0)    384  (31.6) 
Hypercalcemia (Calcium >2.75 mmol/L),  
n(%)  
     
   No     581  (65.2)    235  (72.8)    816  (67.2) 
  Yes    25  (2.8)    5  (1.5)    30  (2.5) 
  Missing data    285  (32.0)    83  (25.7)    368  (30.3) 
Weight Loss >10% During the Last 6 Months, n(%)        
  No     602  (67.6)    241  (74.6)    843  (69.4) 
  Yes    230  (25.8)    65  (20.1)    295  (24.3) 
  Missing data    59  (6.6)    17  (5.3)    76  (6.3) 
Superior Vena Cava Obstruction at Start of  
Therapy, n(%)  
     
  No     850  (95.4)    310  (96.0)    1160  (95.6) 
  Yes    25  (2.8)    5  (1.5)    30  (2.5) 
  Missing data    16  (1.8)    8  (2.5)    24  (2.0) 
Chronic Obstructive Pulmonary Disease at  
Start of Therapy, n(%) 
     
  No     725  (81.4)    253  (78.3)    978  (80.6) 
  Yes    146  (16.4)    60  (18.6)    206  (17.0) 
  Missing data    20  (2.2)    10  (3.1)    30  (2.5) 
Prescribed NSCLC Treatment, n(%)       
  Gemcitabine-carboplatin     306  (34.3)    63  (19.5)    369  (30.4) 
  Gemcitabine-cisplatin     583  (65.4)    260  (80.5)    843  (69.4) 
  Missing data     2  (0.2)    -    2  (0.2) 
Abbreviations: ECOG = Eastern Cooperative Oncology Group; N = total number of patients; n = number of patient in specified category; 
NSCLC = non-small cell lung cancer; SD = standard deviation.  
 
 
 
Table 2. Post Gemcitabine-Platinum Treatment Approaches  
Post Gemcitabine-Platinum Therapy, n(%)  Construction Dataset 
N=891 
Validation Dataset 
N=323 
Total 
N=1214 
Died on Gemcitabine-Platinum Therapy  96   (10.8)  18 (5.6)  114  (9.4) 
No Post Gemcitabine-Platinum Therapy  309   (34.7)  105   (32.5)  414   (34.1) 
Post Gemcitabine-Platinum Therapy*        
  Docetaxel   169   (19.0)  53   (16.4)  222   (18.3) 
  Paclitaxel   57 (6.4)  11 (3.4)  68 (5.6) 
  Vinorelbine   39 (4.4)  14 (4.3)  53 (4.4) 
  Gefitinib  59 (6.6)  29 (9.0)  88 (7.2) 
  Radiotherapy   140   (15.7)  67   (20.7)  207   (17.1) 
  Other   95   (10.7)  34   (10.5)  129   (10.6) 
* Patients may have received more than one post gemcitabine-platinum therapy. 
 
 
 
Effectiveness and Toxicity 
The  median  overall  survival  time  was  12.7 
months (95% CI: 11.5, 13.7; n=1213). On completion of 
study  therapy,  of  the  1214  patients  enrolled,  594 
(48.9%) had no reported progression of disease. Of the 
6 3 7   ( 5 2 . 5 % )   t h a t   d i e d   d u r i n g   t h e   s t u d y ,   t h e   m a j o r i t y  
(95.6%), in the opinion of the investigator, died as a 
result of study disease. Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
56 
Of  the  1214  patients  enrolled,  266  (21.9%)  re-
p o r t e d   a t   l e a s t   o n e   A E .  The most frequently reported 
A E s   w e r e   l o w   h e m o g l o b i n   c o u n t   ( < 8   g / d L ;   n = 1 6 1 ,  
13.3%), low neutrophil count (<1.0x109/L associated 
with fever of ≥38.5°C or documented infection; n=99, 
8.2%),  and  thrombocytopenia  (<50x109/L  with 
bleeding; n=73, 6.0%). 
Univariate Analyses of Survival 
Of 42 prognostic factors analyzed, 16 were found 
by univariate Cox regression analysis to be signifi-
cantly  (p≤0.05)  associated  with  survival,  including 
baseline  smoking  level;  heavy  smoker  at  baseline; 
r a c e ;   c o u n t r y ;   d i s e a s e   s t a g e ;   p e r f o r m a n c e   s t a t u s ;   s u-
perior  vena  cava  obstruction;  age  <70  years;  TNM 
staging; largest tumor >5cm; gender; metastatic liver, 
b o n e   a n d   b r a i n   d i s e a s e ;   d y s p n e a   p r e s e n t ;   c h r o n i c   o b-
str u c t i v e   p u l m o n a r y   d i s e a s e ;   a l b u m i n   ( n o r m a l   r a n g e  
indicator); and lactic dehydrogenase.  
Development and Validation of the Predictive 
Model for Survival 
Firstly,  all  variables  (excluding  smoking  va-
riables) with <10% missing values were included in 
the  initial  Cox’s  model.  A  stepwise  Cox  regression 
was then performed with essential factors identified 
by Brundage et al (2002) [17]. Country, disease stage, 
hypercalcemia, “N” factor, weight reduction, perfor-
mance  status,  and  superior  vena  cava  obstruction 
were forced into the model. A s   a   r e s u l t ,   6   v a r i a b l e s  
were additionally selected by the regression (gemci-
tabine-platinum regimen, T-stage, chronic obstructive 
pulmonary disease, metastatic brain disease, gender, 
and diagnosis). The final predictive model (Figure 1) 
identified four significant (p≤0.05) and independent 
p r e d i c t o r s   o f   s u r v i v a l ,   w h i c h   w e r e   d i s e a s e   s t a g e ,   p e r-
formance status, gemcitabine-platinum regimen, and 
T-stage.  No  smoking  variables  were  represented  in 
the final predictive model. 
C o x   r e g r e s s i o n   p e r f o r m e d   o n   t h e   V a l i d a t i o n   d a-
taset  showed  high  significance  (p=0.0008)  of  linear 
predictor  calculated  using  the  coefficients  estimated 
in the Construction dataset. Patients in the Validation 
dataset (n=323) were also classified into three groups 
based on the predicted one-year survival probabilities 
forecas t   f r o m   t h e   f i n a l   p r e d i c t i v e   m o d e l :   ( 1 )   p r e d i c t e d  
probability  <0.2;  (2)  predicted  probability  ranging 
from ≥0.2 to <0.5; and (3) predicted probability ≥0.5. 
T h e   p r e d i c t e d   a n d   o b s e r v e d   p r o p o r t i o n s   s u r v i v i n g  
w e r e   c a l c u l a t e d   f o r   e a c h   o f   t h e   a b o v e   g r o u p s   ( F i g u re 
2). These analyses support the predictive model being 
strongly associated with actual survival in the Vali-
dation dataset.  
Development of the Predictive Model for Ad-
verse Events 
O f   4 2   p r o g n o s t i c   f a c t o r s   a n a l y z e d ,   6   w e r e   f o u n d  
by univariate logistic regression analysis to be signif-
i c a n t l y   ( p ≤ 0 . 0 5 )   a s s o c i a t e d   w i t h   A E s ,   w h i c h   w e r e  
country,  gemcitabine-platinum  regimen,  largest  tu-
m o r   > 5 c m ,   p r e s e n c e   o f   h e m o p t y s i s ,   p r e s e n c e   o f   p a i n ,  
and albumin.  
T h e   f i n a l   p r e d i c t i v e   m o d e l ,   a s   e s t a b l i s h e d   i n   t h e  
Construction dataset using multivariate stepwise lo-
gistic regression (with gender forced into the model, 
and excluding smoking variables from the selection 
process),  identified  5  significant  (p≤0.05)  and  inde-
p e n d e n t   p r e d i c t o r s   o f   A E s ,   t h a t   b e i n g   d i s e a s e   s t a g e  
(IIIB versu s   I V ) ,   c o u n t r y ,   w e i g h t   l o s s   > 1 0 % ,   a g e   < 7 0  
years,  and  the  presence  of  pain.  The  smoking  va-
r i a b l e s   a d d e d   t o   t h e   e s t a b l i s h e d   m o d e l   d i d   n o t   r e a c h  
significance (p>0.05). 
Effect of Continued Smoking during Therapy on 
Survival and Adverse Events 
Smoking  characteristics at baseline and during 
t h e   s t u d y   a r e   o u t l i n e d   i n   T a b l e   3 .  Overall, 70.8% of 
patients had smoked at some point prior to therapy 
(i.e.  ever  smokers).  Approximately  half  of  ever 
smokers (53.7%) had ceased smoking at initiation of 
therapy or within 6 months prior to treatment start, 
while 11.2% of smokers continued to smoke during 
therapy. O f   t h o s e   p a t i e n t s   c o n t i n u i n g   t o   s m o k e   d u r i n g  
therapy, the mean number of cigarettes smoked per 
day was 16.57 (95% CI: 13.0, 20.1). T h e r e   w a s   n o   s t a-
tistically  significant  difference  in  survival  observed 
between “never smokers” and “ever smokers”, with 
a n   u n a d j u s t e d   H R   ( v e r s u s   n e v e r   s m o k e r s )   o f   1 . 1 4 3  
(95% CI: 0.925, 1.441; p=0.2155). None of the smoking 
variables  forced  into  the  established  multivariate 
model  were  significantly  associated  with  survival, 
with  an  adjusted  HR  of  0.955  (95%  CI:  0.572,  1.596) 
observed  for  continued  smoking  during  therapy 
( v e r s u s   n e v e r   s m o k e r s ;   p = 0 . 8 6 1 8 ) ,   a n d   a n   a d j u s t e d   H R  
of 0.905 (95% CI: 0.648, 1.263) observed for ex-smokers 
(versus  never  smokers;  p=0.5579).  No  statistically 
s i g n i f i c a n t   a s s o c i a t i o n   w a s   o b s e r v e d   b e t w e e n   A E s   a n d  
continued  smoking  during  therapy  (adjusted 
OR=1.297 [95% CI: 0.716, 2.350]; p=0.3912).  
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Figure 1. Final Predictive Model for Survival (Construction Dataset). Abbreviations: adeno = adenocarcinoma; COPD = 
chronic obstructive pulmonary disease; HR = hazard ratio; TNM = tumor, node, metastasis; vs = versus. Journal of Cancer 2011, 2 
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Figure 2. Validation of the Predictive Model: Predicted versus Actual One-Year Survival (Validation Dataset). 
 
 
Table 3. Smoking Characteristics at Baseline and During Study (Construction and Validation Datasets)  
Smoking Characteristic, n(% )  Construction Dataset 
N=891 
Validation Dataset 
N=323 
Total 
N=1214 
Ever Smoked Prior to Therapy        
  No    224 (25.1)   88 (27.2)   312 (25.7) 
  Yes   629 (70.6)   230 (71.2)   859 (70.8) 
   Missing data    38 (4.3)   5 (1.5)   43 (3.5) 
Pack-Years Smoked Prior to Therapy        
  n    620  229  849 
   Mean (95% CI)    45.06  (42.6, 47.6)  49.71 (44.5, 54.9)  46.31  (44.0, 48.6) 
Time from Smoking Cessation to  
Treatment Start for Patients who Ever Smoked Prior to Therapy†  
     
  No cessation   47 (7.5)   32 (13.9)   79 (9.2) 
  Restarted after cessation    36 (5.7)   20 (8.7)   56 (6.5) 
  0 (cessation at Treatment Start)†   46 (7.3)   20 (8.7)   66 (7.7) 
  >0 & <=1mo    129 (20.5)   51 (22.2)   180 (21.0) 
  >1mo & <=6mo    168 (26.7)   47 (20.4)   215 (25.0) 
  >6mo & <=1yr    38 (6.0)   1 (0.4)   39 (4.5) 
  >1yr & <=5yr    75 (11.9)   29 (12.6)   104 (12.1) 
  >5yr & <=10yr    30 (4.8)   10 (4.3)   40 (4.7) 
  >10yr   60 (9.5)   20 (8.7)   80 (9.3) 
   Mean (95% CI), years‡   2.96 (2.38, 3.53)   3.33 (2.17, 4.48)   3.05 (2.53, 3.57) 
Smoking During Therapy§        
  No    801 (89.9)   269 (83.3)   1070 (88.1) 
  Yes#   83 (9.3)   53 (16.4)   136 (11.2) 
   Missing data    7 (0.8)   1 (0.3)   8 (0.7) 
Cigarettes Per Day During Therapy       
  n   83  53  136 
  Mean (95% CI)    15.05  (10.6,  19.5)  18.94  (12.9,  25.0)  16.57 (13.0, 20.1) 
Heavy Smoker as a Proportion of All  
Patients  
     
  No    397 (44.6)   155 (48.0)   552 (45.5) Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
59 
  Yes   447 (50.2)   162 (50.2)   609 (50.2) 
   Missing data    47 (5.3)   6 (1.9)   53 (4.4) 
† Patients who stopped smoking but without giving a stop date should be considered to have stopped just before the start of therapy.  
‡ Patients who stopped & restarted are not included. 
§ Patients who have the cessation date > therapy start date and their ‘No. cigarettes during therapy’ is entered as zero or blank are consi-
dered not smoking during therapy.  
# One patient, who had never smoked prior to therapy, started smoking during therapy. 
 
 
Association of p16 and RASSF1A Methylation 
Status to Baseline Prognostic Factors and Ad-
verse Events 
Methylation  status  of  p16  and  RASSF1A  was 
analyzed  in  86  patients,  with  hypermethylation  ob-
served in 15 (17.4%, p16) and 8 (9.3%, RASSF1A) pa-
tients,  respectively.  Thirty-nine  prognostic  factors 
were analyzed by univariate and multivariate (step-
wise)  logistic  regression.  In  those  with  RASSF1A 
hypermethylation, no factors were identified as sig-
nificant following univariate (n=86) and stepwise lo-
gistic regression (n=65). In those with p16 hyperme-
t h y l a t i o n ,   t h e   f o l l o w i n g   f a c t o r s   w e r e   f o u n d   t o   b e   s i g-
nificant  in  univariate  analyses  (n=86):  performance 
status  (1  versus  0,  unadjusted  OR=10.240  [95%  CI: 
1.276,  82.162]  p=0.0286),  extra-thoracic  metastatic 
disease (yes versus no, unadjusted OR=6.891 [95% CI: 
1.968, 24.124], p=0.0025), and total bilirubin (1µmol/L 
versus 0, unadjusted OR=1.240 [95% CI: 1.037, 1.482], 
p=0.0181). Following stepwise regression (n=65), ex-
tra-thoracic metastatic disease was identified as a sig-
n i f i c a n t   f a c t o r   ( y e s   v e r s u s   n o ,   OR=5.595  [95%  CI: 
1.342, 23.333], p<0.0181). 
Neither p16 nor RASSF1A were significant when 
added  to  the  established  predictive  model  for  AEs. 
Additionally,  the  univariate  logistic  regression  did 
not identify methylation factors as predictive of AEs.  
Discussion 
I n   t h i s   p r o s p e c t i v e ,   o b s e r v a t i o n a l   s t u d y ,   t h e   e f-
f e c t   o f   p r o g n o s t i c   f a c t o r s ,   i n   p a r t i c u l a r   c o n t i n u e d  
smoking  during  therapy,  on  survival  and  other 
treatment  outcomes,  was  assessed  in  patients  with 
advanced NSCLC receiving gemcitabine-platinum as 
first-line therapy. Continued smoking during gemci-
tabine-platinum  therapy  was  not  associated  with 
shorter  survival  in  patients  with  advanced  NSCLC. 
Construction  and  validation  of  a  predictive  model 
identified four independent prognostic factors asso-
ciated with survival: disease stage, performance sta-
tus, gemcitabine-platinum regimen, and T-stage.  
The  greatest  risk  factor  associated  with  lung 
cancer  is  cigarette  smoking  [18-19],  with  approx-
i m a t e l y   8 5 %   o f   a l l   l u n g   c a n c e r   c a s e s   i n   m e n   a n d   4 7 %  
in wom e n   a t t r i b u t e d   t o   t o b a c c o   s m o k i n g   [ 1]. Previous 
studies have identified an association towards longer 
survival  [19],  as  well as  statistically  significant  dif-
ferences in survival [20],  between  “never  smokers” 
and “ever smokers” who have undergone chemothe-
rapy.  Our  study  had  a  similar  proportion  of  never 
s m o k e r s   ( 2 5 . 7 % )   c o m p a r e d   t o   p r e v i o u s   s t u d i e s   ( 1 4 . 5 %  
[21];  16%  [20];  36.3%  [19]).  However,  unlike  these 
other  studies,  there  was  no  statistically  significant 
difference  in  survival  observed  between  “never 
smokers”  and  “ever  smokers”  receiving  gemcita-
bine-platinum  as  first-line  therapy.  A  retrospective 
study by Nguyen et al (2006) in which exploratory 
subgroup analyses were performed, reported similar 
findings to this study, in which no significant differ-
ence in median survival time between “ever smokers” 
and  “never  smokers”  was  observed  in  patients  re-
ceiving gemcitabine-cisplatin therapy [22]. However, 
gemcitabine-cisplatin  was  also  a  therapy  utilized  in 
the study by Scagliotti et al (2008) and an association 
towards  longer  survival  was  observed  in  “never 
smokers” (15.3 months) compared to “ever smokers” 
(10.3  months)  [21].  I n   t e r m s   o f   c o n t inued  smoking 
d u r i n g   t h e r a p y ,   i n   o u r   s t u d y ,   f e w e r   p a t i e n t s   ( 1 1 . 2 % )  
continued  smoking  during  therapy  when  compared 
to a previous study (48%) [20]. It is interesting to note 
that  the  retrospective  study  of  Tsao  et  al  (2006)  en-
compassed patients treated with first-line chemothe-
rapy  between  1993  and  2002  [20],  while  our  study 
reflects  patient  treatment  during  2004-2005.  It  is 
t h e r e f o r e   p o s s i b l e   t h a t   t h e   l o w e r   p r o p o r t i o n   o f   p a-
t i e n t s   c o n t i n u i n g   t o   s m o k e   d u r i n g   t h e r a p y   i n   o u r  
study reflects the increased influence that oncologists 
are having on their patients as well as a greater public 
awareness  of  the  association  between  smoking  and 
lung cancer. D e s p i t e   d i f f e r e n c e s   i n   t h e   p r o p o r t i o n   o f  
patients continuing smoking during therapy, similar 
f i n d i n g s   i n   t e r m s   o f   t h e   i m p a c t   o f   c o n t i n u e d   s m o k i n g  
d u r i n g   t h e r a p y   o n   s u r v i v a l   w e r e   n o t ed between our 
study and Tsao et al (2006), with no statistically sig-
nificant difference in survival observed between those 
patients  continuing  to  smoke  during  therapy  and 
those  who  discontinued  prior  to  therapy  initiation 
[20]. This suggests the detrimental effects of cigarette Journal of Cancer 2011, 2 
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s m o k i n g   m a y   o c c u r   e a r l i e r   i n   d i s e a s e   p rogression. 
A n o t h e r   e x p l a n a t i o n   m a y   b e   t h a t   t h e   e f f e c t s   o f   c o n-
tinued  smoking  during  therapy  are  not  evident  in 
patients treated with chemotherapy in late stage dis-
e a s e   a s   t h e i r   d u r a t i o n   o f   s u r v i v a l   i s   l i m i t e d .   Addi-
t i o n a l l y ,   b i a s   a s   a   r e s u l t   o f   t h e   n o n -randomized,  un-
b l i n d e d   d e s i g n   o f   t h e   s t u d y   a n d   c o n f o u n d i n g   a r e   i n-
herently  associated  with  observational  studies  and 
should  be  considered  when  interpreting  the  results. 
The  effect  of  continued  smoking  during  therapy  on 
toxicity was also analyzed in this study. Although an 
a s s o c i a t i o n   t o w a r d s   a   g r e a t e r   r a t e   o f   A E s   w a s   o b-
served  in  patients  who  continued  to  smoke  during 
therapy, this was not statistically significant.  
I n   a d d i t i o n   t o   s m o k i n g ,   n u m e r o u s   f a c t o r s   h a v e  
b e e n   s h o w n   t o   i n f l u e n c e   s u r v i v a l   a n d   t o x i c i t y   i n   p a-
ti e n t s   w i t h   a d v a n c e d   N S C L C ,   s u c h   a s   d i s e a s e   s t a g e ,  
p e r f o r m a n c e   s t a t u s ,   a g e ,   w e i g h t   l o s s ,   a n d   g e n d e r  
[5,9-12,19-20]. I n   t h i s   s t u d y ,   d e v e l o p m e n t   o f   a   p r e d i c-
tive mod e l   i n   a   C o n s t r u c t i o n   d a t a s e t ,   a n d   s u b s e q u e n t  
validation with a Validation dataset, led to the identi-
fication of four significant (p≤0.05) and independent 
predictors of survival, which were disease stage (IV 
versus IIIB), performance status (ECOG 1 versus 0), 
gemcitabine-platinum  regimen  (carboplatin  versus 
cisplatin), and T-stage (versus T1). Performance status 
h a s   b e e n   s h o w n   i n   a   n u m b e r   o f   t r i a l s   t o   b e   a   p o w e r f u l  
predictor  of  survival  [9,11,19-20,23-25].  Similarly, in 
t h i s   s t u d y ,   p e r f o r m a n c e   s t a t u s   w a s   i d e n t i f i e d   a s   a n  
independent  prognostic  factor,  with  improved  sur-
vival  associated  with  a  better  baseline  performance 
status. I n   t h i s   s t u d y ,   d i s e a s e   s t a g e   w a s   a l s o   i d e n t i f i e d  
as an independent prognostic factor, with improved 
s u r v i v a l   n o t e d   i n   t h o s e   p a t i e n t s   w i t h   G r a d e   I I I B  
N S C L C   w h e n   c o m p a r e d   w i t h   G r a d e   I V   d i s e a s e .  Sim-
ilar findings have been shown in other studies [19,24]. 
T-s t a g e   w a s   a l s o   s h o w n   t o   b e   a n   i n d e p e n d e n t   p r o g-
nostic  factor  in  our  study,  with  improved  survival 
observed  in  patients  with  T1  stage  compared  with 
T2-TX. H e n c e ,   i n   r e l a t i o n   t o   T N M   t h e   p r o g n o s t i c   v a l-
u e   i n   t e r m s   o f   s u r v i v a l   p r e d i c t i o n ,   i n   o u r   s t u d y ,   c a n   b e  
b a s e d   o n   T -stage  alone.  This  is  in  alignment  with 
ASCO  guidelines  [26]. Although platinum combina-
tions with a third-generation chemotherapy agent are 
w i d e l y   r e c o g n i z e d   a s   s t a n d a r d   o f   c a r e   f o r   f i r s t -line 
treatment  of  patients  with  advanced  NSCLC,  the 
choice  of  platinum  agent  (carboplatin  or  cisplatin) 
varies. I n   o u r   s t u d y ,   t h e   c h o i c e   o f   p l a t i n u m   a g ent was 
s h o w n   t o   i n f l u e n c e   s u r v i v a l ,   w i t h   c i s p l a t i n   p r o v i n g   t o  
b e   m o r e   e f f e c t i v e   t h a n   c a r b o p l a t i n .   This  finding  is 
consistent with a meta-analysis, in which carboplatin 
combinations  with  third-generation  chemotherapy 
were shown to be inferior to cisplatin combinations 
with third-generation chemotherapy [27].  
Genetic factors are also involved in lung cancer 
development,  with  aberrant  promoter  methylation 
playing an important role. Previous studies of NSCLC 
have reported varied frequencies of p16 methylation, 
w i t h   W a n g   e t   a l   ( 2 0 0 8 )   r e p o r t i n g   p16 methylation in 
38% of samples [28] ,   w h i l e   G u z m a n   e t   a l   ( 2 0 0 7 )   o b-
served p16 methylation in 79.7% of samples [29]. In 
this  study,  the  p16  methylation  observed  was  low 
(17.6%) compared to observations in previous studies. 
Additionally, RASSF1A methylation has been impli-
cated in NSCLC, with RASSF1A methylation reported 
in 21% [28] and 40% [30]   o f   s a m p l e s ,   w h i l e   i n   t h e  
current study RASSF1A w a s   o b s e r v e d   i n   o n l y   8 . 2 %   o f  
samples. Possible explanations for the different me-
thylation  frequencies  include  techniques  to  study 
methylation status and study population. Wang et al 
(2008)  [28]  utilized  microarray  technology,  while 
Guzman et al (2007) [29], Li et al (2003) [30]   a n d   t h e  
current  study  utilized  PCR-based technology. These 
s t u d i e s   f o c u s e d   o n   s a m p l e s   f r o m   C h i n a   [ 2 8 ] ,   C h i l e   [ 2 9 ]  
and  the  US  [30],  respectively,  whereas  the  current 
study analyzed samples from nine different countries 
(China,  Egypt,  Israel,  Pakistan,  Poland,  Romania, 
South  Korea,  Taiwan,  and  Turkey).  Moreover,  dif-
ferent frequencies of methylation have been observed 
in different NSCLC histological types [29] ,   t h u s   d i f-
f e r e n t   p r o p o r t i o n s   o f   h i s t o l o g i c a l   t y p e s   m a y   b e  
present in each of the different studies.  
The  naturalistic  setting  of  this  study  provides 
insight into the use of gemcitabine-platinum first-line 
therapy  and  treatment  outcomes. In  addition  to  the 
s t r e n g t h s   o f   t h i s   s t u d y ,   w e   a c k n o w l e d g e   s e v e r a l   l i m i-
tations which should be taken into account when in-
terpreting  the  results.  F i r s t l y ,   a s   t h e   n u m b e r   o f   p a-
t i e n t s   e n r o l l e d   i n   t h i s   s t u d y   w a s   r e d u c e d   ( n = 1 2 1 4 )  
c o m p a r e d   w i t h   t h e   p l a n n e d   n u m b e r   ( n = 3 0 0 0 )   t h e  
study was not adequately powered to test the hypo-
thesis  that  smoking  during  chemotherapy  may  be 
a s s o c i a t e d   w i t h   s h o r t e r   s u r v i v a l   i n   p a t i e n t s   w i t h   a d-
vanced NSCLC who receive first-line chemotherapy 
with  gemcitabine-platinum.  Secondly,  there  was  a 
higher than anticipated decrease in smoking during 
therapy.  T h i r d l y ,   t h e   o b s e r v a t i o n a l   n a t u r e   o f   t h e  
study can lead to bias and confounding.  
Conclusions 
This  observational  study  shows  that  continued 
smoking  during  gemcitabine-platinum  therapy  was 
not associated with shorter survival in patients with 
advanced  NSCLC.  Additionally,  construction  and 
validation of a predictive model identified four inde-
pendent prognostic factors that were associated with 
survival - disease stage, performance status, gemcita-
bine-platinum regimen, and T-stage.  Journal of Cancer 2011, 2 
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